

---

<b>Product Name</b>	: NEO2734
<b>Synonyms</b>	: EP31670
<b>Cat No.</b>	: M22391
<b>CAS Number</b>	: 2081072-29-7
<b>Molecular Formula</b>	: C <sub>22</sub> H <sub>24</sub> F <sub>3</sub> N <sub>3</sub> O <sub>3</sub>
<b>Formula Weight</b>	: 435.44
<b>Chemical Name</b>	: —
<b>Description</b>	: NEO2734 is an orally active and selective inhibitor of p300/CBP and BET bromodomain (IC <sub>50</sub> of <30 nM for both p300/CBP and BET bromodomains). NEO2734, a novel dual inhibitor of BET and CBP/p300, is active in both hotspot mutant (F133V) and non-hotspot mutant (Q165P) PCa cells in vitro and in vivo.
<b>Pathway</b>	: Chromatin/Epigenetic
<b>Target</b>	: Epigenetic Reader Domain
<b>Receptor</b>	: p300/CBP; BET bromodomain
<b>Solubility</b>	: —
<b>SMILES</b>	: <chem>Cc1cc(cn(C)c1=O)-c1ccc2nc(C3CCOCC3)n(CCOC(F)(F)F)c2c1</chem>
<b>Storage</b>	: (-20°C)
<b>Stability</b>	: ≥ 2 years
<b>Reference</b>	:

1. The novel BET-CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer.